• Sign In
  • Register
  • Glossary
  • Share/Bookmark
  • RSS
All About Bleeding

References for Therapies

1. Bevan DH. Cryoprecipitate: no longer the best therapeutic choice in congenital fibrinogen disorders? Thromb Res 2009;124 Suppl 2:S12-16.

2. Fenger-Eriksen C, Jensen TM, Kristensen BS, Jensen KM, Tonnesen E, Ingerslev J, et al. Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo-controlled clinical trial. J Thromb Haemost 2009;7(5):795-802.

3. Fenger-Eriksen C, Ingerslev J, Sorensen B. Fibrinogen concentrate--a potential universal hemostatic agent. Expert Opin Biol Ther 2009;9(10):1325-33.

4. Makris M, Watson HG. The management of coumarin-induced over-anticoagulation Annotation. Br J Haematol 2001;114(2):271-80.

5. Hanley JP. Warfarin reversal. J Clin Pathol 2004;57(11):1132-9.

6. Bruce D, Nokes TJ. Prothrombin complex concentrate (Beriplex P/N) in severe bleeding: experience in a large tertiary hospital. Critical care (London, England) 2008;12(4):R105.

7. Lorenz R, Kienast J, Otto U, Egger K, Kiehl M, Schreiter D, et al. Efficacy and safety of a prothrombin complex concentrate with two virus-inactivation steps in patients with severe liver damage. Eur J Gastroenterol Hepatol 2003;15(1):15-20.

8. Schick KS, Fertmann JM, Jauch KW, Hoffmann JN. Prothrombin complex concentrate in surgical patients: retrospective evaluation of vitamin K antagonist reversal and treatment of severe bleeding. Critical care (London, England) 2009;13(6):R191.

9. Staudinger T, Frass M, Rintelen C, Quehenberger P, Wagner O, Stoiser B, et al. Influence of prothrombin complex concentrates on plasma coagulation in critically ill patients. Intensive care medicine 1999;25(10):1105-10.

10. Schoechl H, Nienaber U, Hofer G, Voelckel W, Jambor C, Scharbert G, et al. Goal-directed coagulation management of major trauma patients using thromboelastometry (ROTEM)-guided administration of fibrinogen concentrate and prothrombin complex concentrate. Critical care (London, England) 2010;14(2):R55.

11. Ridley S, Taylor B, Gunning K. Medical management of bleeding in critically ill patients. Cont Edu Anaesth Crit Care & Pain 2007;7(4):116-21.

12. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 Suppl):204S-33S.

13. DeSancho MT, Pastores SM. Part 2: Functions of the liver: Synthetic Function. In: Rodes J, Benhamou J-P, Belei AT, Reicher J, Rizzetto M, editors. Textbook of Hepatology. 3rd ed, 2008:225-63.

14. Pipe SW. Recombinant clotting factors. Thromb Haemost 2008;99(5):840-50.

15. Novo Nordisk. NovoSeven SPC, 2009.

16. Peyvandi F. Results of an international, multicentre pharmacokinetic trial in congenital fibrinogen deficiency. Thromb Res 2009;124 Suppl 2:S9-11.

17. Rahe-Meyer N, Pichlmaier M, Haverich A, Solomon C, Winterhalter M, Piepenbrock S, et al. Bleeding management with fibrinogen concentrate targeting a high-normal plasma fibrinogen level: a pilot study. Br J Anaesth 2009;102(6):785-92.

18. Spahn DR, Cerny V, Coats TJ, Duranteau J, Fernandez-Mondejar E, Gordini G, et al. Management of bleeding following major trauma: a European guideline. Crit Care 2007;11(1):R17.

19. Schochl H, Nienaber U, Hofer G, Voelckel W, Jambor C, Scharbert G, et al. Goal-directed coagulation management of major trauma patients using thromboelastometry (ROTEM(R))-guided administration of fibrinogen concentrate and prothrombin complex concentrate. Crit Care 2010;14(2):R55.

20. Rossaint R, Bouillon B, Cerny V, Coats TJ, Duranteau J, Fernandez-Mondejar E, et al. Management of bleeding following major trauma: an updated European guideline. Crit Care 2010;14(2):R52.

21. O'Shaughnessy DF, Atterbury C, Bolton Maggs P, Murphy M, Thomas D, Yates S, et al. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol 2004;126(1):11-28.

22. AnaesthesiaUK. Blood products, 2009.

23. Wilson SE, Watson HG, Crowther MA. Low-dose oral vitamin K therapy for the management of asymptomatic patients with elevated international normalized ratios: a brief review. CMAJ 2004;170(5):821-4.

24. Vigue B. Bench-to-bedside review: Optimising emergency reversal of vitamin K antagonists in severe haemorrhage - from theory to practice. Crit Care 2009;13(2):209.

25. Castaman G, Tosetto A, Rodeghiero F. Von Willebrand disease. In: Key N, Makris M, O'Shaughnessy D, Lillicrap D, editors. Practical Hemostasis and Thrombosis. Second ed: Wiley-Blackwell, 2009:73-87.

26. Mononine UK Summary of Product Characteristics: CSL Behring, 2008.

27. Brown DL, Kouides PA. Diagnosis and treatment of inherited factor X deficiency. Haemophilia 2008;14(6):1176-82.

28. Ozgonenel B, O'Malley B, Krishen P, Eisenbrey AB. Warfarin reversal emerging as the major indication for fresh frozen plasma use at a tertiary care hospital. Am J Hematol 2007;82(12):1091-4.

29. Bolton-Maggs P, Wilde J. The rarer inherited coagulation disorders. In: Key N, Makris M, O'Shaughnessy D, Lillicrap D, editors. Practical Hemostasis and Thrombosis. Second ed: Wiley-Blackwell, 2009:88-95.

30. Schwartz RA, Klujszo E, Gascon P, McKenna R. Factor XIII. emedicine: Medscape, 2010.

31. Hartung H. Factor XIII Deficiency. emedicine Specialties: Medscape, 2010.


Last Updated: 7/11/2012 3:43 PM
  • E-mail
  • Print
  • Share